These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32276476)

  • 21. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody.
    Szebeni J; Fontana JL; Wassef NM; Mongan PD; Morse DS; Dobbins DE; Stahl GL; Bünger R; Alving CR
    Circulation; 1999 May; 99(17):2302-9. PubMed ID: 10226097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro.
    Neun BW; Barenholz Y; Szebeni J; Dobrovolskaia MA
    Molecules; 2018 Jul; 23(7):. PubMed ID: 30002298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions.
    Moghimi SM
    Drug Discov Today; 2018 May; 23(5):1034-1042. PubMed ID: 29146517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017.
    Ehlken B; Nathell L; Gohlke A; Bocuk D; Toussi M; Wohlfeil S
    Drug Saf; 2019 Mar; 42(3):463-471. PubMed ID: 30535629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs.
    Bavli Y; Winkler I; Chen BM; Roffler S; Cohen R; Szebeni J; Barenholz Y
    J Control Release; 2019 Jul; 306():138-148. PubMed ID: 31176656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug Hypersensitivity Reactions Documented in Electronic Health Records within a Large Health System.
    Wong A; Seger DL; Lai KH; Goss FR; Blumenthal KG; Zhou L
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1253-1260.e3. PubMed ID: 30513361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement activation-related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins.
    Szebeni J
    Curr Drug Deliv; 2005 Oct; 2(4):443-9. PubMed ID: 16305447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement Activation-Related Pathophysiological Changes in Anesthetized Rats: Activator-Dependent Variations of Symptoms and Mediators of Pseudoallergy.
    Dézsi L; Mészáros T; Őrfi E; Fülöp TG; Hennies M; Rosivall L; Hamar P; Szebeni J; Szénási G
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31505853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
    Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
    Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of Risk Stratification for Paclitaxel Hypersensitivity Reactions.
    Otani IM; Lax T; Long AA; Slawski BR; Camargo CA; Banerji A
    J Allergy Clin Immunol Pract; 2018; 6(4):1266-1273.e2. PubMed ID: 28986119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PEGylated liposomes: immunological responses.
    Mohamed M; Abu Lila AS; Shimizu T; Alaaeldin E; Hussein A; Sarhan HA; Szebeni J; Ishida T
    Sci Technol Adv Mater; 2019; 20(1):710-724. PubMed ID: 31275462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Preclinical study on adverse reactions of Xingnaojing injection].
    Yi Y; Li CY; Zhao Y; Pan C; Liu SY; Wang LM; Zhang YS; Han JY; Tian JZ; Liang AH
    Zhongguo Zhong Yao Za Zhi; 2018 Jul; 43(13):2789-2795. PubMed ID: 30111033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review.
    Banerji A; Lax T; Guyer A; Hurwitz S; Camargo CA; Long AA
    J Allergy Clin Immunol Pract; 2014; 2(4):428-33. PubMed ID: 25017531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The Incidence and Management of Hypersensitivity and Infusion Reactions in an Outpatient Chemotherapy Center].
    Sekine H; Akaiwa A; Onozawa Y; Kinjo T; Nakamura H; Nakamura R; Nawa M; Yoshida S; Araki N; Iizuka M; Shimizu H; Sunaga N; Tsukamoto N
    Gan To Kagaku Ryoho; 2018 Nov; 45(11):1625-1629. PubMed ID: 30449851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions.
    Szebeni J; Alving CR; Savay S; Barenholz Y; Priev A; Danino D; Talmon Y
    Int Immunopharmacol; 2001 Apr; 1(4):721-35. PubMed ID: 11357884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Reliable Method for the Evaluation of the Anaphylactoid Reaction Caused by Injectable Drugs.
    Wang F; Weng Z; Li C; Peng G
    Molecules; 2016 Oct; 21(10):. PubMed ID: 27754330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reactions to cytostatic agents in children.
    Cernadas JR
    Curr Opin Allergy Clin Immunol; 2017 Aug; 17(4):255-261. PubMed ID: 28622171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies.
    Koshiba H; Hosokawa K; Kubo A; Miyagi Y; Oda T; Miyagi Y; Watanabe A; Honjo H
    Int J Gynecol Cancer; 2009 Apr; 19(3):460-5. PubMed ID: 19407575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypersensitivity Reactions to Iodinated Contrast Media: A Multicenter Study of 196 081 Patients.
    Cha MJ; Kang DY; Lee W; Yoon SH; Choi YH; Byun JS; Lee J; Kim YH; Choo KS; Cho BS; Jeon KN; Jung JW; Kang HR
    Radiology; 2019 Oct; 293(1):117-124. PubMed ID: 31478801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse and Hypersensitivity Reactions to Prescription Nonsteroidal Anti-Inflammatory Agents in a Large Health Care System.
    Blumenthal KG; Lai KH; Huang M; Wallace ZS; Wickner PG; Zhou L
    J Allergy Clin Immunol Pract; 2017; 5(3):737-743.e3. PubMed ID: 28110055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.